Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Wilkinson (Southampton, United Kingdom), S. Schembri (Dundee, United Kingdom), C. Brightling (Leicester, United Kingdom), N. Bakerly (Salford, United Kingdom), W. Macnee (Edinburgh, United Kingdom), L. Rombo (Uppsala, Sweden), J. Hedner (Göteborg, Sweden), M. Allen (Stoke-on-Trent, United Kingdom), P. Walker (Liverpool, United Kingdom), I. De Ryck (Siena, Italy), A. Tasciotti (Siena, Italy), D. Casula (Siena, Italy), M. Testa (Siena, Italy), A. Arora (Siena, Italy). Late Breaking Abstract - Safety and immunogenicity of non-typeable H. influenzae (NTHi) adjuvanted vaccine in older adults with chronic obstructive pulmonary disease (COPD). 4089

Member's Comments

No comment yet.

Related content which might interest you: Clinical impact of a non-typeable Haemophilus influenzae (NTHi) adjuvanted vaccine in adults with chronic obstructive pulmonary disease (COPD) Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019 Late Breaking Abstract - Safety and immunogenicity of non-typeable H. influenzae (NTHi) and M. catarrhalis (Mcat) adjuvanted vaccines in adults Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018 Alteration of the immune response to nontypeable haemophilus influenzae (NTHI) during COPD exacerbation in mice Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections Year: 2013 Infection pattern and inflammatory response in acute and persistent nontypeable haemophilus influenzae (NTHi) infection of COPD lung tissue Source: Eur Respir J 2006; 28: Suppl. 50, 841s Year: 2006 Safety and immunogenicity of hemophilus influenzae type B conjugate vaccine in COPD Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine Source: Eur Respir J 2002; 20: 813-818 Year: 2002 Influenza and pneumococcal vaccines prevalence and their influance on asthma and chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005 Effectiveness of polysaccharide pneumococcal vaccination among subjects with chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 442s Year: 2006 HI-164, an oral vaccine to non-typable haemophilus influenzae, reduces antibiotic use, respiratory exacerbations and hospitalisations in patients with COPD Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Pneumococcal vaccination coverage in Spanish patients with chronic obstructive pulmonary disease (COPD). Result of the EPIDEPOC study Source: Eur Respir J 2004; 24: Suppl. 48, 144s Year: 2004 Non-typeable Haemophilus influenzae infection of ciliated epithelium from healthy and chronic obstructive pulmonary disease donors Source: International Congress 2018 – The airway microbiome across the spectrum of airway disease Year: 2018 Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 178s Year: 2006 Late Breaking Abstract - Seroprevalence of Bordetella pertussis in chronic obstructive pulmonary disease (COPD) patients Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 Pneumococcal polysaccharide vaccination in COPD patients - some problems with antibody-response Source: Eur Respir J 2002; 20: Suppl. 38, 472s Year: 2002 Pneumococcal vaccination: Effects on exacerbation of COPD Source: Annual Congress 2013 –COPD treatment Year: 2013 No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2007; 30: Suppl. 51, 372s Year: 2007 Real-life effectiveness data on prevention OF COPD and asthma exacerbations with 13-valent pneumococcal conjugate vaccine (PCV13) Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Clinical efficacy of pneumococcal conjugate vaccine in patients with chronic airway disease Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 Pneumococcal vaccine in steroid-dependent COPD Source: Annual Congress 2005 - Acute and chronic infections in COPD Year: 2005